- Home
- OTLY vs ANNX Comparison
OTLY vs ANNX Comparison
Compare OTLY & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLY
- ANNX
- Stock Information
- Founded
- OTLY 1994
- ANNX 2011
- Country
- OTLY Sweden
- ANNX United States
- Employees
- OTLY N/A
- ANNX N/A
- Industry
- OTLY Packaged Foods
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- OTLY Consumer Staples
- ANNX Health Care
- Exchange
- OTLY Nasdaq
- ANNX Nasdaq
- Market Cap
- OTLY 303.5M
- ANNX 263.3M
- IPO Year
- OTLY 2021
- ANNX 2020
- Fundamental
- Price
- OTLY $15.07
- ANNX $2.45
- Analyst Decision
- OTLY Buy
- ANNX Strong Buy
- Analyst Count
- OTLY 5
- ANNX 4
- Target Price
- OTLY $19.60
- ANNX $12.50
- AVG Volume (30 Days)
- OTLY 158.4K
- ANNX 1.7M
- Earning Date
- OTLY 07-23-2025
- ANNX 08-11-2025
- Dividend Yield
- OTLY N/A
- ANNX N/A
- EPS Growth
- OTLY N/A
- ANNX N/A
- EPS
- OTLY N/A
- ANNX N/A
- Revenue
- OTLY $828,200,000.00
- ANNX N/A
- Revenue This Year
- OTLY $4.68
- ANNX N/A
- Revenue Next Year
- OTLY $4.78
- ANNX N/A
- P/E Ratio
- OTLY N/A
- ANNX N/A
- Revenue Growth
- OTLY 4.43
- ANNX N/A
- 52 Week Low
- OTLY $6.00
- ANNX $1.29
- 52 Week High
- OTLY $20.80
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- OTLY 65.35
- ANNX 49.07
- Support Level
- OTLY $14.30
- ANNX $2.46
- Resistance Level
- OTLY $15.50
- ANNX $2.74
- Average True Range (ATR)
- OTLY 0.77
- ANNX 0.18
- MACD
- OTLY -0.02
- ANNX -0.01
- Stochastic Oscillator
- OTLY 83.15
- ANNX 45.28
About OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.